Summary
Aggregates IO trial data, FDA combination therapy guidance, and published IO combination outcomes to support immuno-oncology combination development strategies.
Detailed Description
The Immuno-Oncology Combination Pack addresses the unique regulatory and scientific challenges of developing checkpoint inhibitor combinations, IO/IO combinations, and IO plus targeted therapy regimens. It compiles data from the IO trial registry, FDA guidance on combination drug development, and published combination efficacy and safety data.
The pack analyzes historical IO combination approvals and clinical holds to identify regulatory expectations for contribution assessment, safety monitoring, and dose selection in combination settings. It maps the evolving FDA framework for demonstrating the contribution of each component in a combination regimen.
Deliverables include an IO combination development strategy, a component contribution analysis framework, and a safety signal benchmarking report comparing adverse event profiles across precedent IO combinations in your indication.
Evidence Sources
| Source | Type | Description | Refresh |
|---|---|---|---|
| IO Trial Registry | REGISTRY | Curated registry of immuno-oncology clinical trials including checkpoint inhibitor combinations | Weekly |
| FDA IO Guidance Documents | REGULATORY | FDA guidance on IO drug development, combination therapy evaluation, and endpoint selection | Monthly |
| Published IO Combination Data | LITERATURE | Peer-reviewed publications reporting IO combination efficacy, safety, and translational data | Weekly |
Regulatory Mapping
Codevelopment of Two or More New Investigational Drugs for Use in Combination
Statistical Principles for Clinical Trials
Considerations for the Development of Immuno-Oncology Agents
Agent Transparency
When you run this pack, your request is processed by a pipeline of specialized AI agents. Each agent operates with a defined confidence threshold and is auditable end-to-end.
Evidence Retriever
brew-retriever-v3
Queries curated sources for relevant evidence objects. Searches across regulatory databases, clinical registries, and scientific literature to surface the most pertinent references for the pack domain.
Domain Analyzer
brew-domain-analyst-v2
Applies domain-specific reasoning and regulatory mapping. Interprets evidence in the context of FDA, ICH, and EMA frameworks and tags each finding with the relevant guidance references.
Evidence Synthesizer
brew-synthesizer-v2
Synthesizes findings into structured output. Combines retrieved evidence and domain analysis into a cohesive narrative with quantitative summaries, comparative tables, and actionable recommendations.
Output Validator
brew-validator-v1
Validates citations, checks confidence thresholds, and ensures all referenced sources are accessible and correctly attributed. Flags any claims that fall below the confidence floor.
Sample Outputs
IO Combination Strategy Document
PDFComprehensive development strategy for the IO combination including contribution assessment framework
Component Contribution Analysis
PDFFramework for demonstrating the contribution of each combination component with statistical considerations
Safety Benchmarking Report
XLSXComparative adverse event profile analysis across precedent IO combinations in the target indication
Deliverables included
- IO combination development strategy (20-30 pages)
- Component contribution assessment framework
- Safety benchmarking across precedent IO combinations
- Dose selection rationale for combination regimen
- Regulatory pathway analysis for combination approval
Related Disease & Biomarker Mappings
| Therapeutic Area | Disease Family | Key Biomarkers | Relevance |
|---|---|---|---|
| Solid Tumors | Non-Small Cell Lung Cancer | EGFRALKPD-L1KRAS G12C | Primary |
| Solid Tumors | Breast Cancer | HER2ER/PRBRCA1/2PIK3CA | Primary |
| Hematologic Malignancies | Acute Myeloid Leukemia | FLT3-ITDIDH1/2NPM1 | Secondary |
| Solid Tumors | Colorectal Cancer | KRAS/NRASBRAF V600EMSI-H/dMMR | Secondary |
Related Packs in Oncology
Oncology Trial Design Pack
Design smarter trials with real-world precedent data
Dose Optimization Pack (Project Optimus)
Navigate the new dose optimization paradigm with confidence
Biomarker-Driven Trial Design Pack
Turn molecular insights into registration-ready trial designs
Accelerated Approval Evidence Pack
Build a bulletproof accelerated approval submission
Version History
Current release — expanded evidence sources, improved citation accuracy, and added new regulatory cross-references.
Beta release — validated with domain SMEs. Added sample output previews and refined confidence scoring.
Initial draft — core evidence retrieval pipeline and output schema established.
Need a Custom Evidence Pack?
Our enterprise team can build bespoke evidence packs tailored to your therapeutic area, regulatory strategy, or internal decision framework. Custom packs include dedicated evidence source curation, domain-specific agent tuning, and priority SLA support.
Enterprise packs are available for organizations on the BrewBio Pro or Enterprise plan.